Masaki Hiramoto

Dr. Masaki Hiramoto


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2018 in Diabetologia
Verified
Journal Article
Closed access
PDF file
TNTakao Nammo
Takao Nammo
HUHaruhide Udagawa
Haruhide Udagawa
NFNobuaki Funahashi
Nobuaki Funahashi
MKMiho Kawaguchi
Miho Kawaguchi
TUTakashi Uebanso
Takashi Uebanso
KYKazuki Yasuda
Kazuki Yasuda

4 March 2023 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
NTNaoharu Takano
Naoharu Takano
MHMasaki Hiramoto
Masaki Hiramoto
YYYumiko Yamada
Yumiko Yamada
HKHiroko Kokuba
Hiroko Kokuba
MTMayumi Tokuhisa
Mayumi Tokuhisa
KMKeisuke Miyazawa
Keisuke Miyazawa
Background: Autophagy plays an important role in tumour cell growth and survival and also promotes resistance to chemotherapy. Hence, autophagy has been targeted for cancer therapy. We previously reported that macrolide antibiotics including azithromycin (AZM) inhibit autophagy in various types of cancer cells in vitro. However, the underlying molecular mechanism for autophagy inhibition remains unclear. Here, we aimed to identify the molecular target of AZM for inhibiting autophagy. Methods: We identified the AZM-binding proteins using AZM-conjugated magnetic nanobeads for high-throughput affinity purification. Autophagy inhibitory mechanism of AZM was analysed by confocal microscopic and transmission electron microscopic observation. The anti-tumour effect with autophagy inhibition by oral AZM administration was assessed in the xenografted mice model. Results: We elucidated that keratin-18 (KRT18) and α/β-tubulin specifically bind to AZM. Treatment of the cells with AZM disrupts intracellular KRT18 dynamics, and KRT18 knockdown resulted in autophagy inhibition. Additionally, AZM treatment suppresses intracellular lysosomal trafficking along the microtubules for blocking autophagic flux. Oral AZM administration suppressed tumour growth while inhibiting autophagy in tumour tissue. Conclusions: As drug-repurposing, our results indicate that AZM is a potent autophagy inhibitor for cancer treatment, which acts by directly interacting with cytoskeletal proteins and perturbing their dynamics.

30 August 2021 in International Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
MMMasaya Miyazaki
Masaya Miyazaki
MHMasaki Hiramoto
Masaki Hiramoto
NTNaoharu Takano
Naoharu Takano
HKHiroko Kokuba
Hiroko Kokuba
JTJun Takemura
Jun Takemura
KMKeisuke Miyazawa
Keisuke Miyazawa
The autophagy‑lysosome system allows cells to adapt to environmental changes by regulating the degradation and recycling of cellular components, and to maintain homeostasis by removing aggregated proteins and defective organelles. Cyclin G‑associated kinase (GAK) is involved in the regulation of clathrin‑dependent endocytosis and cell cycle progression. In addition, a single nucleotide polymorphism at the GAK locus has been reported as a risk factor for Parkinson's disease. However, the roles of GAK in the autophagy‑lysosome system are not completely understood, thus the present study aimed to clarify this. In the present study, under genetic disruption or chemical inhibition of GAK, analyzing autophagic flux and observing morphological changes of autophagosomes and autolysosomes revealed that GAK controlled lysosomal dynamics via actomyosin regulation, resulting in a steady progression of autophagy. GAK knockout (KO) in A549 cells impaired autophagosome‑lysosome fusion and autophagic lysosome reformation, which resulted in the accumulation of enlarged autophagosomes and autolysosomes during prolonged starvation. The stagnation of autophagic flux accompanied by these phenomena was also observed with the addition of a GAK inhibitor. Furthermore, the addition of Rho‑associated protein kinase (ROCK) inhibitor or ROCK1 knockdown mitigated GAK KO‑mediated effects. The results suggested a vital role of GAK in controlling lysosomal dynamics via maintaining lysosomal homeostasis during autophagy.

1 February 2000 in Experimental Hematology
Verified
Journal Article
Closed access
SAShin Aizawa
Shin Aizawa
MHMasaki Hiramoto
Masaki Hiramoto
HHHajime Hoshi
Hajime Hoshi
KTKeisule Toyama
Keisule Toyama
DSDaisuke Shima
Daisuke Shima
HHHiroshi Hagiwara;Hiroshi Handa
Hiroshi Hagiwara;Hiroshi Handa

24 December 2021 in Oncology Reports
Verified
Journal Article
Open access
PDF file
SSSumire Suzuki
Sumire Suzuki
MOMasato Ogawa
Masato Ogawa
MMMasaya Miyazaki
Masaya Miyazaki
KOKohki Ota
Kohki Ota
HKHiromi Kazama
Hiromi Kazama
KMKeisuke Miyazawa
Keisuke Miyazawa
Pancreatic cancer is one of the leading causes of cancer‑related mortality and has the lowest 5‑year survival rate. Therefore, novel strategies are urgently required to treat pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) cells rely on enhanced lysosomal function for survival and proliferation to facilitate the degradation of contents accumulated via autophagy and macropinocytosis. Previously, we have reported that the combination of epidermal growth factor receptor/HER2 inhibitor lapatinib and sphingosine analog fingolimod (FTY720) confers a significant cytostatic effect in lung cancer cells. In the present study, the combined effects of these drugs on PDAC cell lines, BxPC‑3, KP‑4, PANC‑1 and MIA PaCa‑2, were examined. It was observed that FTY720 enhanced the lapatinib‑induced cytotoxic effect and caused non‑canonical and lysosome‑dependent death in PDAC cells. Lapatinib and FTY720 induced lysosomal swelling and inhibited lysosomal acidification. Combination treatment with lapatinib and FTY720 increased lysosomal membrane permeability, induced mitochondrial depolarization, induced endoplasmic reticulum stress and disturbed intracellular calcium homeostasis. Additionally, the cytotoxic effect of lapatinib was enhanced by hydroxychloroquine or the CDK4/6 inhibitor abemaciclib, both of which induce lysosomal dysfunction. Collectively, these results indicated that the lysosome‑targeted drug combination induces multiple organelle dysfunction and exerts a marked cytotoxic effect in PDAC cells.

2 May 2019 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
KOKohki Ota
Kohki Ota
TOTakashi Okuma
Takashi Okuma
ALAlberto Lorenzo
Alberto Lorenzo
AYAyuka Yokota
Ayuka Yokota
HHHirotsugu Hino
Hirotsugu Hino
KMKeisuke Miyazawa
Keisuke Miyazawa
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase and mutations in this gene are major drivers of lung cancer development. EGFR tyrosine kinase inhibitors (TKIs) are standard first-line therapies for patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations, but are not effective in patients with wild-type EGFR. In the present study, the cytotoxic effects of various TKIs against EGFR were investigated in wild-type NSCLC cells as single treatments or in combination with Fingolimod (FTY720), which has been approved for treating multiple sclerosis and has cytotoxic effects against several tumor cell lines. It was found that the combined treatment with TKIs lapatinib (Lap) or sorafenib (Sor) and FTY720 synergistically suppressed the viability of the NSCLC cell lines A549 and H596. Additionally, FTY720 inhibited lysosomal acidification and suppressed autophagy flux. Immunoblotting and reverse transcription-quantitative polymerase chain reaction showed that FTY720 combined with Lap or Sor, enhanced endoplasmic reticulum (ER) stress loading and cell cycle arrest in A549 cells. The enhancement of ER stress loading and cell cycle arrest induced by combined treatment with Lap or Sor and FTY720, which was associated with the cytotoxicity induced by the combination of these drugs. These findings suggested that FTY720 improved TKI therapy in NSCLC patients with wild-type EGFR, by sensitizing NSCLC cells to TKIs.